Skip to main content
Signal8

Chimeric Therapeutics Limited (CHMMF)

Sector: Biotechnology

Industry: Biotechnology

Chimeric Therapeutics Limited logo

Chimeric Therapeutics Limited

OTC:CHMMFHealthcare
Mkt Cap$4.1M
EV-
Float26.23M
O/S41.04M
Inst Own-
Net Cash/Sh-
Dilution
Historical Data
DateOpenHighLowCloseVolume
Nov 12, 20260.10000.10000.10000.100030,000
Nov 9, 20260.10000.10000.10000.100030,000
Nov 6, 20260.10000.10000.10000.100030,000
Nov 3, 20260.10000.10000.10000.100030,000
Nov 2, 20260.10000.10000.10000.100030,000
Oct 30, 20260.10000.10000.10000.100030,000
Oct 29, 20260.10000.10000.10000.100030,000
Oct 26, 20260.10000.10000.10000.100030,000
Oct 23, 20260.10000.10000.10000.100030,000
Oct 20, 20260.10000.10000.10000.100030,000
Oct 19, 20260.10000.10000.10000.100030,000
Oct 16, 20260.10000.10000.10000.100030,000
Oct 15, 20260.10000.10000.10000.100030,000
Oct 12, 20260.10000.10000.10000.100030,000
Oct 9, 20260.10000.10000.10000.100030,000
Oct 6, 20260.10000.10000.10000.100030,000
Oct 5, 20260.10000.10000.10000.100030,000
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About

Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer.

Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoing Phase I clinical trials for the treatment of both solid tumors and hematological malignancies. Another key program, CHM 1101 (a CLTX CAR T-cell therapy), is also in Phase I development, specifically targeting patients with recurrent or progressive glioblastoma that expresses MMP2. Beyond these lead programs, the company is actively developing a range of other innovative therapies. These include CHM 0301 for various blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK), both designed to combat solid tumors. The CLTX CAR T-cell therapy, CHM 1101, is additionally being explored for indications such as melanoma, colorectal, and prostate cancers. Furthermore, CHM 2101 (CDH17 CAR T) is under development for neuroendocrine, colorectal, pancreatic, and gastric cancers. Established in 2020, Chimeric Therapeutics Limited maintains its headquarters in Carlton, Australia.

Key Metrics
Market Cap$4.10M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 41.04M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeOTC
CountryAUAU
IPO Date-
Shares Outstanding41.04M
Authorized Shares
Float26.23M
52-Week Range
Volume
Average Daily Volume30.00K

30d Avg

30.00K

60d Avg

30.00K

90d Avg

30.00K

Earnings
Dividend History
No dividend history available